Massachusetts Institute of Technology

Brian A Donahue

Stephen J Lippard

Patti Jean Kellett

John M Essigmann

Jeffrey H Toney

Pieter M Pil

Suzanne L Bruhn

Steven J Brown

Steven Joel Brown

Methods disclosed herein capitalize on the ability of DNA Structure Specific Recognition Proteins (SSRPs) to bind to genomic lesions formed by chemotherapeutic agents, particularly cisplatin-type agents. Methods are provided for predicting whether an agent that damages DNA will also be cytotoxic, and for predicting whether particular eukaryotic cells will be susceptible to killing by a genotoxic drug. A screening method is provided for identifying new genotoxic drugs that produce SSRP-recognized lesions in DNA. Methods also are provided for sensitizing particular eukaryotic cells to killing by chemotherapeutic agents, particularly cisplatin-type drugs.

Uses for DNA structure-specific recognition protein

DNA structure specific recognition protein of eukaryotic origin and DNA encoding such a factor, as well as probes specific for DNA structure specific recognition protein or DNA encoding it and methods of detecting DNA structure specific recognition protein in eukaryotic cells. In particular, a mammalian cellular factor that selectively recognizes and binds DNA damaged or modified by a drug (the anticancer drug, cis-diamminedichloroplatinum (II) or cisplatin) has been identified.

DNA structure specific recognition protein complexes

Nucleic acids encoding DNA structure-specific recognition protein and

Growing community of inventors

Menlo Park, CA, United States of America

Brian A Donahue